Gainers

• Profusa (NASDAQ:PFSA) stock increased by 126.9% to $1.72 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million.
• Soleno Therapeutics (NASDAQ:SLNO) stock increased by 32.74% to $52.42. The company's market cap stands at $2.1 billion.
• PRF Technologies (NASDAQ:PRFX) shares increased by 21.45% to $2.55. The market value of their outstanding shares is at $1.7 million.
• Aditxt (NASDAQ:ADTX) stock moved upwards by 15.81% to $0.92.
• Annovis Bio (NYSE:ANVS) stock rose 12.92% to $2.57. The company's market cap stands at $64.6 million.
• iSpecimen (NASDAQ:ISPC) shares rose 11.46% to $0.16. The company's market cap stands at $1.3 million. As per the press release, Q4 earnings came out 3 days ago.

Losers

• Cyclerion Therapeutics (NASDAQ:CYCN) shares decreased by 13.2% to $5.34 during Monday's pre-market session. The market value of their outstanding shares is at $23.4 million.
• Imunon (NASDAQ:IMNN) stock fell 11.81% to $2.84. The market value of their outstanding shares is at $10.9 million. The company's, Q4 earnings came out 4 days ago.
• Virax Biolabs Group (NASDAQ:VRAX) shares declined by 11.56% to $0.15. The market value of their outstanding shares is at $1.2 million.
• Agape ATP (NASDAQ:ATPC) shares fell 11.36% to $2.81. The market value of their outstanding shares is at $3.1 million.
• Cocrystal Pharma (NASDAQ:COCP) stock declined by 10.27% to $1.35. The company's market cap stands at $20.8 million. The company's, Q4 earnings came out 4 days ago.
• GlucoTrack (NASDAQ:GCTK) shares fell 8.38% to $0.79. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.